Table 2. Factors associated with LLV.
| Univariate |
Multivariable model |
|||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Male sex | 0.805 | 0.552–1.173 | 0.259 | |||
| Age | 1.009 | 0.995–1.023 | 0.207 | |||
| Treatment-naïve | 1.312 | 0.874–1.971 | 0.190 | |||
| Treatment | ||||||
| First-line drugs | reference | reference | ||||
| Non-first-line drugs | 2.806 | 1.928–4.085 | 0.000 | 2.929 | 1.925–4.455 | 0.000 |
| Non-first-line drugs combined with first-line drugs | 6.458 | 2.372–17.580 | 0.000 | 5.846 | 2.014–16.970 | 0.001 |
| Baseline ALT<100, U/L | 1.946 | 1.366–2.773 | 0.000 | 2.544 | 1.680–3.852 | 0.000 |
| Baseline HBV DNA > 6 log10, IU/L | 1.578 | 1.133–2.198 | 0.007 | 2.200 | 1.437–3.370 | 0.000 |
| Cirrhosis | 0.992 | 0.692–1.423 | 0.965 | |||
| HBeAg-positive | 1.855 | 1.315–2.618 | 0.000 | 1.400 | 0.936–2.094 | 0.102 |
| Month 6 HBV DNA >3 log10, IU/L | 5.609 | 3.107–10.126 | 0.000 | 3.343 | 1.754–6.372 | 0.000 |
LLV, low-level viremia; OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen.